Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $439.8 million.

  • Allogene Therapeutics' Liabilities and Shareholders Equity fell 2535.12% to $439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 2020.67%. This contributed to the annual value of $548.7 million for FY2024, which is 1464.24% down from last year.
  • Per Allogene Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $439.8 million for Q3 2025, which was down 2535.12% from $470.6 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Liabilities and Shareholders Equity peaked at $1.2 billion during Q1 2021, and registered a low of $439.8 million during Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $750.1 million (2023), whereas its average is $776.5 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 7124.25% in 2021, then plummeted by 2725.22% in 2025.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then dropped by 21.82% to $821.6 million in 2022, then fell by 21.76% to $642.8 million in 2023, then fell by 14.64% to $548.7 million in 2024, then fell by 19.85% to $439.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $439.8 million for Q3 2025, versus $470.6 million for Q2 2025 and $508.0 million for Q1 2025.